{"id":34523,"date":"2025-05-30T19:18:17","date_gmt":"2025-05-30T11:18:17","guid":{"rendered":"https:\/\/flcube.com\/?p=34523"},"modified":"2025-05-30T19:18:17","modified_gmt":"2025-05-30T11:18:17","slug":"cspc-pharmaceutical-in-advanced-talks-for-5b-licensing-deals","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=34523","title":{"rendered":"CSPC Pharmaceutical in Advanced Talks for $5B Licensing Deals"},"content":{"rendered":"\n<p>China-based CSPC Pharmaceutical Group Ltd (<a href=\"https:\/\/www.google.com\/finance\/quote\/1093:HKG\">HKG: 1093<\/a>) revealed that it is currently in negotiations with several independent third-parties regarding three potential licensing deals. These deals involve an epidermal growth factor receptor (EGFR)-targeted antibody-drug conjugate (ADC) and other drug candidates developed using CSPC&#8217;s proprietary technology platforms. The proposed collaborations would cover development, manufacturing, and commercialization rights.<\/p>\n\n\n\n<p><strong>Potential Deal Structure and Value<\/strong><br>Each potential transaction could include upfront payments, development milestone payments, and commercialization milestone payments. The total aggregate value of these deals could potentially reach USD 5 billion, highlighting the significant potential of CSPC&#8217;s drug candidates and technology platforms in the global market.<\/p>\n\n\n\n<p><strong>Progress and Timeline<\/strong><br>One of the three deals has now progressed to late-stage negotiations and is expected to be finalized by June 2025. CSPC emphasized that the specific terms and conditions remain under discussion. The company will issue further announcements as appropriate, ensuring transparency for stakeholders.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2025053000194_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2025053000194_c.\"><\/object><a id=\"wp-block-file--media-52c1a59b-d9f1-4af6-9961-0a33900d1eb0\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2025053000194_c.pdf\">2025053000194_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2025053000194_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-52c1a59b-d9f1-4af6-9961-0a33900d1eb0\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) revealed that it is currently in negotiations with&#8230;<\/p>\n","protected":false},"author":1,"featured_media":34525,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[35,171,855],"class_list":["post-34523","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-adc-xdc","tag-cspc-pharmaceutical","tag-hkg-1093"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>CSPC Pharmaceutical in Advanced Talks for $5B Licensing Deals - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) revealed that it is currently in negotiations with several independent third-parties regarding three potential licensing deals. These deals involve an epidermal growth factor receptor (EGFR)-targeted antibody-drug conjugate (ADC) and other drug candidates developed using CSPC&#039;s proprietary technology platforms. The proposed collaborations would cover development, manufacturing, and commercialization rights.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=34523\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CSPC Pharmaceutical in Advanced Talks for $5B Licensing Deals\" \/>\n<meta property=\"og:description\" content=\"China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) revealed that it is currently in negotiations with several independent third-parties regarding three potential licensing deals. These deals involve an epidermal growth factor receptor (EGFR)-targeted antibody-drug conjugate (ADC) and other drug candidates developed using CSPC&#039;s proprietary technology platforms. The proposed collaborations would cover development, manufacturing, and commercialization rights.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=34523\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-05-30T11:18:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/3010.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34523#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34523\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"CSPC Pharmaceutical in Advanced Talks for $5B Licensing Deals\",\"datePublished\":\"2025-05-30T11:18:17+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34523\"},\"wordCount\":163,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34523#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/3010.webp\",\"keywords\":[\"ADC \\\/ XDC\",\"CSPC Pharmaceutical\",\"HKG: 1093\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=34523#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34523\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=34523\",\"name\":\"CSPC Pharmaceutical in Advanced Talks for $5B Licensing Deals - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34523#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34523#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/3010.webp\",\"datePublished\":\"2025-05-30T11:18:17+00:00\",\"description\":\"China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) revealed that it is currently in negotiations with several independent third-parties regarding three potential licensing deals. These deals involve an epidermal growth factor receptor (EGFR)-targeted antibody-drug conjugate (ADC) and other drug candidates developed using CSPC's proprietary technology platforms. The proposed collaborations would cover development, manufacturing, and commercialization rights.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34523#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=34523\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34523#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/3010.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/3010.webp\",\"width\":1080,\"height\":608,\"caption\":\"CSPC Pharmaceutical in Advanced Talks for $5B Licensing Deals\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34523#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CSPC Pharmaceutical in Advanced Talks for $5B Licensing Deals\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"CSPC Pharmaceutical in Advanced Talks for $5B Licensing Deals - Insight, China&#039;s Pharmaceutical Industry","description":"China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) revealed that it is currently in negotiations with several independent third-parties regarding three potential licensing deals. These deals involve an epidermal growth factor receptor (EGFR)-targeted antibody-drug conjugate (ADC) and other drug candidates developed using CSPC's proprietary technology platforms. The proposed collaborations would cover development, manufacturing, and commercialization rights.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=34523","og_locale":"en_US","og_type":"article","og_title":"CSPC Pharmaceutical in Advanced Talks for $5B Licensing Deals","og_description":"China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) revealed that it is currently in negotiations with several independent third-parties regarding three potential licensing deals. These deals involve an epidermal growth factor receptor (EGFR)-targeted antibody-drug conjugate (ADC) and other drug candidates developed using CSPC's proprietary technology platforms. The proposed collaborations would cover development, manufacturing, and commercialization rights.","og_url":"https:\/\/flcube.com\/?p=34523","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-05-30T11:18:17+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/3010.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=34523#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=34523"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"CSPC Pharmaceutical in Advanced Talks for $5B Licensing Deals","datePublished":"2025-05-30T11:18:17+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=34523"},"wordCount":163,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=34523#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/3010.webp","keywords":["ADC \/ XDC","CSPC Pharmaceutical","HKG: 1093"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=34523#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=34523","url":"https:\/\/flcube.com\/?p=34523","name":"CSPC Pharmaceutical in Advanced Talks for $5B Licensing Deals - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=34523#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=34523#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/3010.webp","datePublished":"2025-05-30T11:18:17+00:00","description":"China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) revealed that it is currently in negotiations with several independent third-parties regarding three potential licensing deals. These deals involve an epidermal growth factor receptor (EGFR)-targeted antibody-drug conjugate (ADC) and other drug candidates developed using CSPC's proprietary technology platforms. The proposed collaborations would cover development, manufacturing, and commercialization rights.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=34523#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=34523"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=34523#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/3010.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/3010.webp","width":1080,"height":608,"caption":"CSPC Pharmaceutical in Advanced Talks for $5B Licensing Deals"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=34523#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"CSPC Pharmaceutical in Advanced Talks for $5B Licensing Deals"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/3010.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/34523","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=34523"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/34523\/revisions"}],"predecessor-version":[{"id":34526,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/34523\/revisions\/34526"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/34525"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=34523"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=34523"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=34523"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}